MedTrace Logo

Reward-based Technology to Improve OUD Treatment

NCT05180669 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2026-02-06

Study results available
· View outcomes & findings →

Summary

Millions of people in the US misuse opioids each year. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious, but only a fraction of OUD persons access MAT, and treatment non-adherence is common and associated with poor outcomes. This project will utilize a digital mobile platform, Opioid Addiction Recovery Support with contingency management (OARSCM), to increase MAT treatment initiation and adherence among OUD patients recruited from emergency departments and inpatient acute care.

Conditions

Interventions

OTHER

OARSCM Software Application

Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.

OTHER

MyMAT Software Application

Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.

Sponsors & Collaborators

  • University of Massachusetts, Worcester

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Q2i, LLC

    lead INDUSTRY

Principal Investigators

  • Rachel Davis-Martin, PhD · University of Massachusetts Chan Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-18
Primary Completion
2025-05-31
Completion
2025-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05180669 on ClinicalTrials.gov